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Abstract
Background—Obesity and breast cancer risk is multifaceted and genes associated with energy 
homeostasis may modify this relationship.
Methods—We evaluated 10 genes that have been associated with obesity and energy 
homeostasis to determine their association with breast cancer risk in Hispanic/Native American 
(2111 cases, 2597 controls) and non-Hispanic white (1481 cases, 1585 controls) women.
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Results—Cholecystokinin (CCK) rs747455 and proopiomelanocortin (POMC) rs6713532 and 
rs7565877 (for low Indigenous American (IA) ancestry); CCK rs8192472 and neuropeptide Y 
(NYP) rs16141 and rs14129 (intermediate IA ancestry); and leptin receptor (LEPR) rs11585329 
(high IA ancestry) were strongly associated with multiple indicators of body size. There were no 
significant associations with breast cancer risk between genes and SNPs overall. However, LEPR 
was significantly associated with breast cancer risk among women with low IA ancestry (PARTP = 
0.024); POMC was significantly associated with breast cancer risk among women with 
intermediate (PARTP = 0.015) and high (PARTP = 0.012) IA ancestry. The overall pathway was 
statistically significant for pre-menopausal women with low IA ancestry (PARTP = 0.05), as was 
cocaine and amphetamine regulated transcript protein (CARTPT) (PARTP = 0.014) and ghrelin 
(GHRL) (PARTP = 0.007). POMC was significantly associated with breast cancer risk among post-
menopausal women with higher IA ancestry (PARTP = 0.005). Three SNPs in LEPR (rs6704167, 
rs17412175, and rs7626141), and adiponectin (ADIPOQ); rs822391) showed significant 4-way 
interactions (GxExMenopausexAncestry) for multiple indicators of body size among pre-
menopausal women.
Conclusions—Energy homeostasis genes were associated with breast cancer risk; menopausal 
status, body size, and genetic ancestry influenced this relationship.
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1. Introduction
The association between obesity and risk of breast cancer is complex, with differences in 
associations being reported by menopausal status, hormone receptor status of tumor, and 
ethnicity [1–4]. Studies that have included Hispanic women suggest significant inverse 
associations with BMI among pre-menopausal women, and either no association or an 
inverse association between BMI and breast cancer risk among post-menopausal women, 
but a positive association with weight gain, particularly among those who were lean in 
young adulthood. These findings suggest that the associations between obesity and breast 
cancer risk are multifaceted and may be influenced by genetic makeup. Considerable 
evidence from both human and animal studies suggests that genes play an important role in 
regulating obesity and energy homeostasis [5,6].
We hypothesize that genetic variation in genes that are associated with obesity, energy 
homeostasis, and satiety may help explain differences observed for breast cancer 
associations between pre- and post-menopause and indicators of body size. Additionally, 
genetic variation in energy homeostasis genes may help explain the influence of race and 
ethnicity on breast cancer risk. We examine 10 genes, including adiponectin (ADIPOQ), 
cocaine and amphet-amine regulated transcript protein (CARTPT), cholecystokinin (CCK), 
ghrelin/obestatin prepropeptide (GHRL), leptin (LEP), leptin receptor (LEPR), Membrane 
bound O-acyltransferase domain containing 4 (MBOAT4), melanocortin 4 receptor (MC4R), 
neuropeptide Y (NPY), and proopiomelanocortin (POMC), and evaluate their associations 
with body size measures and with breast cancer risk. Both adiponectin and leptin are 
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adipokines that are secreted by adipocytes [7]. Leptin has been directly associated with 
obesity, while adiponectin has been inversely associated with obesity and visceral fat 
accumulation [8]. Among these genes, LEP and LEPR have been studied the most with 
breast cancer and have been associated with obesity [9]. Several studies have evaluated 
polymorphisms in these genes with breast cancer, with conflicting results [10–16]. However, 
consideration of level of obesity as a component of risk has generally not been done, 
although the study by Llanos suggested that BMI level may influence risk associated with 
both leptin and adiponectin [9]. Several of our target genes including, CARTPT, CCK, 
MC4R, NPY, and POMC, are neuropeptides involved in the regulation of appetite and 
satiety. GHRL is involved in energy homeostasis and regulation of body weight through its 
influence on satiety. Polymorphisms in GHRL have been linked to breast cancer risk as well 
as to obesity and insulin levels [17]. MBOAT4 codes the ghrelin O-acyltransferase (GOAT) 
enzyme that acrylates ghrelin to enable its endocrine actions [18].
In this study, we focus on energy homeostasis genes to evaluate associated breast cancer risk 
in an ethnically diverse population. In this hypothesis-driven study, we evaluate pre- and 
post-meno-pausal breast cancer risk separately given differences in reported association with 
BMI for these groups. Additionally we consider Indigenous American (IA) ancestry to better 
understand the contribution of the underlying genetic ancestry in this ethnically diverse 
population that may be modifying breast cancer risk associated with these energy 
homeostasis genes. Our hypothesis is that the energy homeostasis pathway will be 
associated with breast cancer risk and associations will vary by IA ancestry as well as by 
menopausal status.
2. Methods
Data from the Breast Cancer Health Disparities Study that includes participants from three 
population-based case-control studies [19], the 4-Corners Breast Cancer Study (4-CBCS) 
[1], the Mexico Breast Cancer Study (MBCS), and the San Francisco Bay Area Breast 
Cancer Study (SFBCS) [2,20,21] who completed an in-person interview and who had a 
blood or mouthwash sample available for DNA extraction were used. In the 4-CBCS, 
participants were between 25 and 79 years; participants from the MBCS were between 28 
and 74 years; the SFBCS included women aged 35–79 years. The 4-CBCS consisted of 
population-based breast cancer cases and controls from Arizona, Colorado, New Mexico and 
Utah who were diagnosed between October 1999 and May 2004. Of cases contacted, 852 
Hispanic, 22 American Indian, and 1683 NHW women participated. Of controls contacted, 
913 Hispanic, 23 American Indian, and 1669 NHW women participated. Blood was 
collected and DNA extracted for 76% of participants in Arizona, 71% of participants in 
Colorado, 75% of participants in New Mexico, and 94% of participants in Utah. Of 
participants contacted, 63% of Hispanic and 71% of NHW cases participated; for controls 
these numbers were 36% and 47% respectively. For the MBCS, cases were diagnosed 
between January 2004 and December 2007. A total of 1000 cases and 1074 controls were 
recruited, and blood was collected and DNA extracted from 85% and 96% of women, 
respectively. The SFBCS included breast cancer cases diagnosed between April 1997 and 
April 2002. DNA was available for 93% of cases and 92% of controls interviewed, 
including 1105 cases (793 Hispanics, 312 NHW) and 1318 controls (998 Hispanics, 320 
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NHW). Participation was 89% for cases and 92% for controls contacted. All participants 
signed informed written consent prior to participation and the Institutional Review Board for 
Human Subjects approved the study at each institution.
3. Data harmonization
Data were harmonized across all study centers and questionnaires as previously described 
[19]. In the United States, women were ask to self-report their race/ethnicity and were 
classified as non-Hispanic white (NHW) if they reported no Hispanic or Native American 
(NA) ancestry. Women who reported any Hispanic or NA ancestry were classified 
accordingly. Women also were classified as either pre-menopausal or post-menopausal 
based on responses to questions on menstrual history. Women who reported still having 
periods during the referent year (defined as the year before diagnosis for cases or before 
selection into the study for controls) were classified as pre-menopausal. Women were 
classified as post-menopausal if they reported either a natural or surgically-induced 
menopause or if they reported taking hormone therapy (HT) and were still having periods or 
were at or above the 95th percentile of age for those who reported having a natural 
menopause (i.e., ≥12 months since their last period). Women were categorized as having a 
positive family history of breast cancer if they reported having a first-degree relative with 
breast cancer.
Body size indicators used were body mass index (BMI) of weight (kg)/height (m)2, weight 
gain since young adult, waist circumference (an indicator of central obesity), hip 
circumference, waist-to-hip ratio (WHR) as a measure of body fat distribution, and waist-to-
height ratio (WHtR) as an indicator of visceral adiposity independent of height. These 
indicators were chosen given previous associations with breast cancer [4]. Weight was based 
on self-reported weight during the reference year or weight measured at interview if weight 
during the reference year was not available. Height was based on measured height at 
interview or self-reported height if the measurement was declined. Categories of BMI were 
normal BMI (<25.0 kg/m2), overweight (25.0–29.9 kg/ m2), or obese ( 30 kg/m2). In the 
SFBCS, young-adult BMI was based on self-reported weight at age 25–30 years for cases 
diagnosed from 1995 to 1998 and their matched controls, or on self-reported weight at age 
20–29 years for cases diagnosed from 1998 to 2002 and their matched controls. In the 4-
CBCS and MCBCS, young-adult BMI was based on the average weight reported at ages 15 
years and 30 years. Weight gain (in kg) was calculated as the difference between self-
reported young-adult weight and self-reported weight in the reference year (or measured 
weight at interview if self-reported weight was not available). Women who lost weight were 
excluded from weight gain analyses. Current BMI was categorized as underweight to normal 
weight (<25.0 kg/m2), overweight (25.0–29.9 kg/m2), or obese (≥30.0 kg/m2). All other 
body size variables were categorized according to the tertile distribution among controls.
4. Genetic data
DNA was extracted from either whole blood (n = 7287) or mouthwash (n = 634) samples. 
Whole genome amplification (WGA) was applied to the mouthwash-derived DNA samples 
prior to genotyping. A tag SNP approach was used to characterize variation across candidate 
Slattery et al. Page 4













genes. Tag SNPs were selected using the following parameters: linkage disequilibrium (LD) 
blocks were defined using a Caucasian LD map of validated SNPS and an r2 = 0.8; minor 
allele frequency (MAF) > 0.1; range = −1500 bps from the initiation codon to +1500 bps 
from the termination codon; and 1 SNP/LD bin. Additionally, 104 ancestry informative 
markers (AIMs) were used to distinguish European and IA ancestry in the study population 
[19]. All markers were genotyped using a multiplexed bead array assay format based on 
Golden Gate chemistry (Illumina, San Diego, California). A genotyping call rate of 99.93% 
was attained (99.65% for WGA samples). We included 132-blinded internal replicates 
representing 1.6% of the sample set. The duplicate concordance rate was 99.996% as 
determined by 193,297 matching genotypes among sample pairs. In the current analysis we 
evaluated tag SNPs for ADIPOQ (12 SNPs), CARTPT (5 SNPs), CCK (4 SNPs), GHRL (8 
SNPs), LEP (9 SNPs), LEPR (27 SNPs), MBOAT4 (1 SNP), MC4R (3 SNPs), NPY (4 
SNPs), and POMC (5 SNPs). These genes and SNPs are described in online Supplement 
Table 1. As shown in Supplemental Table 1, 57 of the SNPs evaluated had a significant 
difference in MAF between NHW and Hispanic/NA women, while 25 SNPs were not 
significantly different in MAF between these two groups.
5. Statistical methods
5.1. Genetic ancestry estimation
The program STRUCTURE was used to compute individual ancestry for each study 
participant assuming two founding populations [22,23]. A three-founding population model 
was assessed but did not fit the population structure. Participants were classified by percent 
IA ancestry. Assessment across categories of ancestry was done using cut-points, 0–28%, 
29–70%, and 71–100%, based on the distribution of genetic ancestry in the control 
population with the goal of creating distinct ancestry groups with sufficient power to assess 
breast cancer risk. Previous analysis with these ancestry categories has shown that they 
relate significantly to breast cancer risk [19]. In assessing interaction with body size factors, 
the two upper IA groups were combined to provide more power.
5.2. Robust regression
Robust regression was used to estimate associations between candidate genes/SNPs and 
body size variables of BMI, weight gain, waist circumference, hip circumference, WHR, and 
WHtR by ancestry among controls. Body size variables were transformed prior to 
assessment to meet the normalization requirement. Beta coefficients and p values for linear 
trend are provided for the three ancestry groups.
5.3. SNP associations
All statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC). 
Conditional logistic regression models were used to estimate odds ratios (OR) and 95% 
confidence intervals (CI) for breast cancer risk associated with SNPs, adjusting for study as 
a categorical variable and age, genetic ancestry, body mass index (BMI, kg/m2) in the 
referent year, vigorous physical activity level during the referent year, alcohol consumption, 
and parity all as continuous variables Total energy intake was not included as a covariate in 
the final models because adjustment for total energy intake altered risk estimates by less 
Slattery et al. Page 5













than 0.01. Since we observed no differences in association by in situ and invasive for the 4-
CBCS, we included all women in the analysis of breast cancer risk. Associations with SNPs 
were assessed assuming a co-dominant model. Based on the initial assessment, SNPs that 
appeared to have a dominant or recessive mode of inheritance, were subsequently evaluated 
with those inheritance models. Genes and SNPs were assessed for their association with 
breast cancer risk by strata of genetic ancestry and menopausal status.
5.4. ARTP analysis
We used the adaptive rank truncated product (ARTP) method that utilizes a highly efficient 
permutation algorithm to determine the significance of association of each gene and of all 
genes combined with breast cancer risk overall, by menopausal status, and by genetic 
ancestry strata. The gene p values were generated using the ARTP package in R, permuting 
outcome status 10,000 times while using same adjustments as in the original analysis 
[26,27]. ARTP analysis adjust for number of genes being assessed within the pathway 
(energy homeostasis pathway) to determine the overall pathway significance and the number 
of SNPs within a gene to determine the gene significance. We report those genes and related 
SNPs that contributed to the gene significance in the tables. We presented raw and adjusted 
SNP p values; adjustments for multiple comparisons for SNPs within the gene used the step-
down Bonferroni correction, taking into account the correlated nature of the data using the 
SNP spectral decomposition method proposed by Nyholt [24] and modified by Li et al. [25].
Tests for interaction across menopausal and genetic ancestry groups were calculated using a 
Wald one degree of freedom (1-df) test. To look at interactions that took into account 
ancestry, menopausal status, anthropometric measure, and SNP we utilized the step-down 
Bonferroni correction to adjust for multiple comparisons. We report those results that had a 
three-way interaction of SNP, body size indicator, and ancestry where the p value was 
<0.15.
6. Results
The mean age was 56.6 and 56.0 year for NHW controls and cases respectively; and 52.3 
years and 52.7 years for U.S. Hispanic/NA/Mexican controls and cases (Table 1). The 
majority of women were post-menopausal. Virtually all women who self-reported being 
NHW had low IA ancestry, while the majority of those who self-reported being 
Hispanic/NA or were from Mexico had intermediate (64.9% of controls and 66% of cases) 
or high (24.4% of controls and 21.0% of cases) IA ancestry.
Several genes were associated with body size variables, although the associations with 
specific genes and SNPs varied by IA ancestry (Table 2). Among women with low IA 
ancestry (<28%) LEPR (1 SNP) was associated with BMI. POMC rs1866146 and rs6713532 
were associated with waist and hip circumference and WHtR, POMC rs7565877 was 
associated with WHR, and POMC rs934778 was associated with WHtR. Among women 
with high IA ancestry (>70%), SNPs in ADIPOQ was associated with WHR (2 SNPs) and 
weight gain (1 SNP); LEP (1 SNP) was associated with hip circumference; GHRL rs26802 
was associated with weight gain while GHRL rs3755777 was associated with hip 
circumference. LEPR was associated with weight gain (1 SNP), waist circumference (1 
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SNP), hip circumference (1 SNP), WHR (2 SNPs) and WHtR (1 SNP). Several markers 
were associated with two or more anthropometric measures among the intermediate IA 
ancestry group, including SNPs in LEPR, CCK, NPY, and POMC.
There were no significant associations with breast cancer risk between genes and SNPs 
overall; however, associations were observed within specific IA ancestry strata (Table 3). 
LEPR was significantly associated with breast cancer risk among women with low IA 
ancestry (PARTP = 0.024) and was marginally associated among women with the highest IA 
ancestry (PARTP = 0.075). Four SNPs (rs1171271, rs4370791, rs1938484, and rs6588147) in 
LEPR were significantly associated with reduced breast cancer risk for the homozygote rare 
genotype among women with low IA ancestry. Among women with high IA ancestry, three 
LEPR SNPS (rs12145690, rs1180445, and rs1475397) were associated with reduced breast 
cancer risk for the homozygote rare genotype, while rs4655802 was associated with 
increased risk for the rare homozygote genotype. Five of these SNPs were significantly 
different by ancestry group, while the others were of marginally significant by ancestry 
group (p range 0.07–0.08). POMC was significantly associated with breast cancer risk 
among women with intermediate (PARTP = 0.015) and high IA ancestry (PARTP = 0.012). 
Three POMC SNPS, rs1866146, rs6713532, and rs934778 contributed to the reduced risk in 
these groups.
Assessment of breast cancer risk by menopausal status showed that among pre-menopausal 
women, the overall pathway was statistically significant for pre-menopausal women with 
low IA ancestry (PARTP = 0.05). CARTPT was significantly associated with risk of pre-
menopausal breast cancer among all women (PARTP = 0.014) and those with low IA 
ancestry (PARTP = 0.015) (Table 4). GHRL also was associated with breast cancer risk 
among pre-menopausal women with low IA ancestry (PARTP = 0.007). POMC was 
significantly associated with breast cancer risk among post-menopausal women with high IA 
ancestry (PARTP = 0.005). The association with LEPR was of borderline significance for 
post-menopausal women with low IA ancestry (PARTP = 0.06) and for women with 
intermediate IA ancestry (PARTP = 0.08) (data not shown in table).
We assessed interaction between energy homeostasis genes and anthropometric variables by 
genetic ancestry in combination with menopausal status. Associations for the most part were 
limited to pre-menopausal women (Tables 5; numbers associated with Table 5 are provided 
in online Supplement Table 2). Five SNPs in LEPR (rs6704167, rs17412175, rs10749754, 
and rs7526141), and ADIPOQ rs822391 showed significant 3- and 4-way interactions (gene 
× body size × menopausal status × ancestry) for multiple indicators of body size. LEPR 
rs17412175 and rs6704167 and ADIPOQ rs17300539 interacted with BMI, while ADIPOQ 
rs822391 interacted with WHR and WHtR (Table 5). Additionally several LEPR SNPs 
interacted with weight gain, WHR, and hip circumference among pre-menopausal women 
with significantly stronger associations in women with lower IA ancestry. There were few 
associations among post-menopausal women (data not shown in table). Among women with 
a BMI ≥ 30 kg/m2 reduced risks were found among those with LEPRAA rs6704167 (OR 
0.65, 95% CI 0.46– 0.92; p interaction G × BMI 0.024) or LEPRTT rs17412175 (OR 0.68, 
95% CI 0.47–0.97; p interaction G × BMI 0.027).
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In this study, we found that genetic variation among genes that regulate energy homeostasis 
were associated with body size as well as with breast cancer risk. Among certain subgroups 
of the population, LEPR, ADIPOQ, POMC, GHRL appeared to have the greatest influence 
on body size measures and breast cancer risk. These genes (LEPR, GHRL, ADIPOQ) are 
involved in hormonal signaling from distant peripheral tissues that communicate the state of 
energy homeostasis within the body. POMC functions in the arcuate nucleus of the 
hypothalamus as a transducer of peripheral signals in regard to energy stress and modulation 
of satiety [28]. Breast cancer risk was influenced both by menopausal status and IA 
ancestry; body size further modulated risk indicating the multifaceted nature of the disease.
The observed associations with genes were not consistent across body size indicators or 
ancestry groups. Focusing on the strongest associations (p < 0.01) was most insightful. SNPs 
in that category were CCK rs747455 and POMC rs6713532 and rs7565877 for those with 
the least IA ancestry; CCK rs8192472 and NYP rs16141 and rs14129 for those with 
intermediate IA ancestry; and LEPR rs11585329 for those with the most IA ancestry. The 
importance of these SNPs is further supported by the observation that they were associated 
with multiple indicators of body size; the associations with CCK rs8192472 and NPY 
rs16141 and rs16129 were highly significant with almost all indicators of body size. CCK is 
a satiety hormone and has been associated with obesity. CCK rs8192472 specifically has 
been reported as being associated with obesity and was identified as a predictor of obesity in 
GWAS [29]. We found that CCK rs8192472 was marginally associated with breast cancer 
risk among women with high IA ancestry after adjustment for multiple comparisons (data 
not shown, OR = 0.55, 95% CI 0.33–0.91; p = 0.02 and padj 0.059). Two of the four SNPs 
analyzed for NPY were associated with all but one of the body size indicators. NPY is a 
neuropeptide, operating within the arcuate nucleas, a major integrator of appetite control in 
the hypothalamus and is associated with satiety. A functional polymorphism of NYP 
(rs16147) has been associated with leptin levels and WHR among women [30]; rs16147 is in 
high LD with rs16129 (R2 > 0.9). NPY rs16131 has been associated with obesity and 
metabolic syndrome in young children [31]. Our findings support the hypothesis that genetic 
variation in NPY is associated with body size among women with low IA ancestry. LEPR 
has been associated repeatedly with obesity and body size, although we did not find reports 
specifically for rs11585329, the SNP for which we observed the strongest association.
Associations with breast cancer risk became evident when considering IA ancestry and 
menopausal status.LEPR and POMC were associated with breast cancer risk when stratified 
by IA ancestry, with LEPR having stronger associations among women with low IA 
ancestry and POMC having stronger associations among women with high IA ancestry. 
CARTPT and GHRL were associated with breast cancer risk mainly among pre-menopausal 
women with low IA ancestry, while POMC was associated with breast cancer risk among 
post-menopausal women with high IA ancestry. We could not find reports of previous 
associations between CARTPT and breast cancer; however, mutations in CARTPT have been 
associated with reduced metabolic rate, obesity, and diabetes [32]. GHRL, a mediator of 
growth hormone release [33], has been examined more extensively with breast cancer risk, 
with several studies showing no association [34,35], although a modest association with 
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rs171407 has been observed [17]. GHRL rs35683 and rs35682 from our platform were in 
high LD with rs171407 (R2 > 0.80); we saw a significant inverse association with breast 
cancer risk for both of these SNPs among pre-menopausal women with low IA ancestry. 
Although no reported associations between POMC and breast cancer were identified in the 
literature, there is biological plausibility for associations to exist, given the role of POMC in 
appetite control and obesity, including early onset obesity [36,37]. It is possible that women 
with greater IA ancestry may be susceptible to variation in this gene given, a higher 
prevalence of diabetes and early onset obesity. This could be from obesity itself or from 
intake of specific foods that may further influence breast cancer risk.
The leptin-signaling pathway is positively associated with obesity and has been shown to 
stimulate the growth of human breast cancer cells. Furthermore, leptin may induce 
aromatase activity increasing the amount of estrogen in adipose tissue [12]. Leptin can 
activate POMC and inhibit NPY [38] and is involved in inflammatory response and 
regulation of insulin sensitivity. While we did not observe associations between LEP SNPs 
and breast cancer risk, similar to reports by others [8,10,39], we did observe several 
associations between LEPR and breast cancer risk. The biological effects of LEP are exerted 
through binding to the leptin receptor. This receptor is expressed in a variety of immune 
cells and has been shown in breast cancer cell lines to have direct communication with 
estrogen receptor alpha [40]. Others have reported associations between LEPR and risk of 
breast cancer [15]; rs1137101 has been most commonly studied [11,34]. Of the 27 SNPs we 
examined in LEPR, 15, including rs1137101, were associated with breast cancer risk. The 
majority of associations we observed were among women with low IA ancestry. Although 
few studies have evaluated associations by IA ancestry, differences in association by African 
ancestry with LEPR variants have been reported. In our study, we observed that the 
prevalence of genotypes differed by ancestry, with lower MAF frequency among women 
with higher IA ancestry, making associations less precise and more difficult to detect in this 
group. Body size in conjunction with menopausal status and IA ancestry further influenced 
the observed risk between SNPs and breast cancer risk. Significant interactions were 
generally observed for pre-menopausal women and low IA ancestry. Significant interactions 
have been reported between various LEPR SNPS and several indicators of body size which 
we evaluated in relation to breast cancer risk, including BMI, weight gain, hip 
circumference, waist circumference, WHR, and WHtR. Some studies have shown stronger 
associations with LEPR among obese individuals, while others have not [11,39]. The 
functionality of the SNPs is unclear; however, it is likely that they are correlated with 
disruption or enhancement of the leptin-signaling pathway. Leptin levels have been 
correlated with estrogen levels [40], therefore the observation of a stronger effect among 
pre- menopausal women is plausible. It is possible that in the presence of estrogen, genetic 
variation in the LEPR has a greater influence on the biological properties of leptin
Adiponectin, like leptin, is an adipokine. Variation in ADIPOQ has been linked to breast 
cancer risk in some studies [41]. Similar to LEPR, associations in our study were observed 
only among pre- menopausal women and were influenced by BMI and WHR. Others have 
shown a correlation between ADIPOQ rs17366568 and serum levels of adiponectin among 
white women, but not among African American women [42]. However, we did not observe 
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that SNP as being associated with breast cancer risk in any ancestry group. Likewise, 
ADIPOQ rs1501299 was associated with breast cancer risk among African Americans in the 
Women’s Health Initiative but not among Hispanic women [43]; we did not observe a 
significant association between that SNP and breast cancer risk. Adiponectin can regulate 
the secretion of estrogens, TNF, and IGF; circulating levels of adiponectin are decreased in 
obese and diabetic subjects [41,44]. It also has been hypothesized that adiponection may 
have anti-carcinogenic effects based on its ability to decrease the production of reactive 
oxygen species [45]. Obesity likewise can lead to both insulin and leptin resistance resulting 
in what has been labeled as “dysfunctional adipose tissue” [46,47]. As adipose tissue 
expands the composition of adipose tissue changes, adipokines such as leptin and 
inflammatory cytokines increase while adiponectin decreases. This dysfunction from 
increased adipose tissue plays a critical role in insulin resistance, inflammation, and level of 
endogenous sex steroids [47]. Thus, the interaction between indicators of obesity and 
ADIPOQ SNPs, like those with LEPR, could impact breast cancer risk via multiple 
mechanisms [7]. If these SNPs alter the level of adiponectin, the effect on breast cancer risk 
could jointly depend on level of obesity and related adiponectin levels. For instance, if a 
person with a BMI > 30 kg/m2 had a genotype that increased adiponectin levels, their 
resulting adiponectin level could be comparabletoan individual with a different genotype 
who was of normal weight; conversely the level of estrogen, TNF, or IGF could be 
influenced by SNPs that influence adiponectin levels.
The study has limitations and several strengths. Perhaps the greatest weakness is interpreting 
the findings given that the functionality of most of the SNPs is unknown. We used a tagSNP 
approach to gather information on the genetic variation across the gene. However, other 
important SNPs may be outside of the range we used for tagSNP selection and may 
importantly influence our candidate genes in terms of breast cancer risk. Our tagSNP 
approach was implemented on a customized Illumina platform and included SNPs that were 
validated and considered to have a high probability of yielding results. We were able to 
simultaneously evaluate SNPs, body size measurements, menopausal status and IA ancestry, 
although we do not know how estrogen, insulin, and actual levels of leptin and adiponectin 
are expressed in these subgroups; estrogen receptor and progesterone receptor status are not 
available for the entire population. Given the study design we were unable to assess levels of 
leptin or adiponectin. Our sample was large and we were able to examine associations 
simultaneously by level of IA ancestry and menopausal status, which we believe is a 
strength. However, statistical power is always an issue when examining subgroups, and it is 
also a consideration for this study. Given the much lower MAF for many SNPs in categories 
of higher IA ancestry, study power is further compromised and lack of associations in those 
groups could be influenced by sample size. Because of power issues when evaluating 
interactions we combined the upper two ancestry groups given similar associations with 
breast cancer risk in the majority of the previous analysis. However, meaningful inter- 
actions could have been missed given the broader classification and the sample size needed 
to detect interactions. Other factors that influence energy homeostasis, such as total energy 
intake and food composition were not included given the complicated nature of these 
analyses that would involve looking at similar interactions as those presented here and is 
beyond the scope of this manuscript.
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Our findings support the hypothesis that genetic variation in genes involved in energy 
homeostasis is associated with breast cancer risk. Associations were generally stronger for 
pre-menopausal women, although POMC was associated with risk among post-menopausal 
women with high IA ancestry. LEPR, CCK, GHRL, and ADIPOQ were associated with 
breast cancer risk; however, factors such as level of IA ancestry and body size further 
modified risk. These findings provide insight into the complexity of factors that impact 
breast cancer risk and should be replicated in other large admixed populations. To better 
understand breast cancer risk associated with genetic ancestry, it is necessary to consider the 
complex relationship between genes, anthropometric, and meno-pausal status.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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